The accumulation of misfolded proteins is a pathological characteristic common to neurodegenerative disorders such as Alzheimer's, Parkinson's, Huntington's, and prion diseases. Prion diseases are unique in this group by virtue of the selfpropagating and transmissible nature of the misfolded prion protein (40) . The prion replicates itself by converting soluble protein into the insoluble prion conformation. Only one prion protein has been identified in mammals, PrP, and its conversion into the prion conformation causes neurodegenerative diseases (40) . Intriguingly, multiple proteins that behave as prions have been discovered in fungi, but these self-propagating elements do not cause disease (49) . Investigation of fungal prions has provided much support for the prion hypothesis and has introduced several new tools to study prion propagation (11) .
In Saccharomyces cerevisiae, the essential translation termination factor Sup35p can propagate as a prion called [PSI ϩ ] (48). Cells containing the [PSI ϩ ] prion exhibit increased nonsense suppression (48) , presumably because the prion aggregates preclude the Sup35 protein from participating as efficiently in translation termination. The increase in nonsense suppression due to the [PSI ϩ ] state can be observed in yeast cells harboring premature stop codons in nutritional markers, thereby allowing the prion state to be monitored phenotypically (11) .
Since the function of the mammalian prion protein is unknown, it is difficult to determine how mutations in PrP affect function and phenotype. Inherited prion diseases arise as a result of mutations in the gene encoding PrP, PRNP, some of which may favor the formation of the infectious prion conformation, PrP Sc (52) . Intriguingly, patients harboring diseaseassociated PRNP mutations often present with highly variable phenotypes. Even members of one family carrying identical PRNP mutations can present with unique symptoms, including variations in age of disease onset, disease severity, and disease duration (16, 24, 27) .
Mutations that result in expansion of the PrP oligopeptide repeat (ORE) domain (ORD) are associated with dominant, inherited prion diseases (52) . Insertional mutations have been identified in patients that expand the number of repeats up to 14 (27) . Transgenic mice containing a 14-PrP repeat expansion, Tg PrP(PG14), develop a neurological disease similar to that of humans with inherited OREs (12, 13) . The ORD is thought to be dispensable for PrP to form infectious PrP Sc (41) , but the PrP(PG14) protein accumulates in PrP Sc -like deposits that are abundant in the brains of Tg PrP(PG14) mice (12, 13) . These aggregates are not infectious (14) , but protein aggregates from patients harboring other PrP OREs have been demonstrated to be transmissible to primates (7) . Thus, it remains unclear how PrP repeat expansions cause disease.
Conversely, how amino acid sequence changes correlate to alterations in prion propagation has been determined for some yeast prion proteins. The sequence necessary for the conversion of Sup35p into the prion state has been defined by domain mapping and mutagenesis studies (reviewed in reference 54). The prion-forming domain (PFD) has been localized to the N terminus of Sup35p and is necessary and sufficient for prion propagation (30, 46) . The PFD has a strikingly high percentage of glutamine (Q) and asparagine (N) amino acids, and mutation of certain Q or N residues eliminates [PSI ϩ ] (17) . Interestingly, one region in the Sup35p PFD is strikingly similar to a region in PrP, the ORD (6). Sup35p contains 5 1 / 2 OREs, and the ORD of PrP contains five octapeptide repeats. Deletion of one or more Sup35p repeats prevents efficient propagation of [PSI ϩ ] (31, 38) . Alternatively, expansion of the Sup35p ORD results in enhanced prion conversion (31) , suggesting that the ORD of Sup35p influences the de novo formation of the prion state.
In order to investigate the aggregation propensity associated with the PrP repeats and the effect of disease-associated repeat expansions, we developed a novel model system in yeast. Previous research demonstrated that one PrP repeat can replace one Sup35p repeat and maintain prion competence in yeast (38) , suggesting that PrP repeats may structurally mimic the Sup35p repeats. Here, we replaced the entire repeat region of Sup35p with various PrP repeat lengths and determined that the resulting chimeric proteins can behave as prions in yeast. Interestingly, we found that the PrP repeat sequence altered prion stability. The insertion of the longest repeat region (14-PrP ORE) resulted in the strongest prion phenotype and enhanced phenotypic variability. In addition, spontaneous conversion of the chimeric proteins to the prion state was dramatically increased in comparison to that of wild-type Sup35p, but only in the presence of [RNQ ϩ ]. Additional experiments demonstrated that the 14-PrP ORE could replace the N-terminal Q/N-rich region of the Sup35p PFD and successfully maintain and propagate a prion. Taken together, our results indicate that the ORE of PrP is more prion competent and enhances phenotypic variability compared to the wild-type PrP repeat length. We suggest that these properties may contribute to the variability associated with inherited prion disorders in humans.
MATERIALS AND METHODS
Strain construction. All of the yeast strains used in this study were derivatives of 74-D694 (MATa or MAT␣ ade1-14 trp1-289 his3⌬-200 ura3-52 leu2-3,112) (10) . Yeast cells were grown and manipulated by standard techniques (22) . A 74-D694 [PSI ϩ ] diploid with one copy of SUP35 replaced with a kanamycin resistance cassette (sup35::KanMX4) was transformed with a plasmid containing SUP35 (pYK810) (38) . Haploid progeny cells containing pYK810 and sup35::KanMX4 were obtained (74-D694 pYK810) from the diploid. The isogenic [psi Ϫ ] 74-D694 pYK810 strain was created by growth on rich medium (YPD) (22) containing 3 mM guanidine hydrochloride (GdHCl). The plasmid shuffle technique was used to create strains expressing only the Sup35p-PrP chimera (SP5, SP14, and P14MC strains). Plasmid construction. SUP35-PrP chimeras were created by precise replacement of the repeat region of Sup35p (amino acids 40 to 96) with the octapeptide repeats of PrP. To create the chimeric Sup35-PrP plasmids, a 5Ј fragment of SUP35 that added a 5Ј BamHI restriction site and had the endogenous EcoRV site was cloned into an intermediate vector. The resulting plasmid was cut with HindIII and EcoRV to insert the various repeat regions of PrP containing DNA encoding 5, 8, 11, and 14 repeats. The repeat regions of PrP were PCR amplified from plasmids containing mouse PrP with 5, 8, 11, and 14 repeats (D. Harris, unpublished data) with primers A (5Ј-GGTTATCAAGCTTACAATGCTCAA GCCCAACCTCAGGGTGGCACCTGG-3Ј) and B (5Ј-ACCAGCTTGATATC CTTGCAAATTGTTATTGTAGTTGAAGTTTTTGTAATTTCCACGTTGG CCCCATCCACCGCC-3Ј). The DNA sequence of PrP was verified by DNA sequencing, and the resulting translated repeat region for wild-type PrP was as expected (PQGGTWGQ PHGGGWGQ PHGGSWGQ PHGGSWGQ PHGG GWGQ). The PrP repeat expansion amino acid sequence was PQGGTWGQ PHGGGWGQ (PHGGSWGQ PHGGSWGQ PHGGGWGQ) n , in which PrP with 8 repeats contained n ϭ 2, PrP with 11 repeats contained n ϭ 3, and PrP with 14 repeats contained n ϭ 4. The chimeric fragments were removed from the intermediate vector by BamHI and EcoRV and cloned into pUCK1512 (38) , which contained the rest of SUP35. The full-length chimeras were removed with XhoI (blunted) and BamHI from pUKC1512 and cloned into p413TEF (35) cut at the BamHI and SmaI sites. The resulting Sup35p-PrP chimeras with 5, 8, 11, and 14 PrP repeats were called SP5, SP8, SP11, and SP14, respectively. The positive control plasmid (pSup35) with the wild-type SUP35 sequence was created in the same manner. The P14MC plasmid was created by PCR amplification of the 14 PrP repeats with primers B and C (5Ј-CGGGATCCATGTCGCCTC AGGGTGGCACCTGG-3Ј), and the resulting fragment was cloned into pUKC1512 cut at the BamHI and EcoRV sites. The SP5-PFD-green fluorescent protein (GFP) and SP14-PFD-GFP fusion constructs were made by PCR amplification of the specific PFD region of the chimeras with primers 5ЈGGCGC AGGATCCATGTCGGATTCAAACCAA-3Ј and 5ЈGCGCCGCGGATCGTT AACAACTTCGTCATCCAC-3Ј, and the products were digested with the BamHI and SacII restriction enzymes. The products were cloned into a SUP35-PFD-GFP plasmid (mCNMG) (39) Sedimentation properties were analyzed as described previously with the addition of the mini EDTA-free protease inhibitor cocktail (Roche) to the ST buffer (36) . Large aggregates were separated by semidenaturing detergent agarose gel electrophoresis (SDD-AGE) as previously described (1), with the following minor changes. Lysis buffer contained the mini EDTA-free protease inhibitor cocktail (Roche), and the lysates were incubated in sample buffer for 7 min at room temperature before electrophoresis. Sup35p and Sup35p-PrP chimeras were detected with a rabbit polyclonal antibody against the middle region of Sup35p that is maintained in all chimeras, antiSup35 (39) .
PFD-GFP microscopy. Cells were transformed with a copper-inducible plasmid containing either an SP5-PFD-GFP or an SP14-PFD-GFP fusion, and fluorescence microscopy was performed after expression of the fusion protein was induced in log-phase cells with 50 M copper for 1 h (39) .
Curing by overexpression of Hsp104p. Hsp104p overexpression was induced from a galactose-inducible plasmid expressing Hsp104p (pYS-Gal104) by growth in minimal medium lacking uracil (liquid or plates) supplemented with 2% galactose and 1% raffinose, and final colony color was assessed on YPD (10).
Protein transformation. (i) Spheroplasting of cells. 74-D694 [prion Ϫ ] cells were grown to an OD 600 of ϳ0.5 and harvested. The cell pellet was washed successively with 10 ml of water, 10 ml of 1 M sorbitol, and 1 ml of SCE buffer (1 M sorbitol, 10 mM EDTA, 10 mM dithiothreitol, 100 mM sodium citrate, pH 5.8). The cells were spheroplasted in 500 l of SCE buffer with lyticase (in sodium citrate, pH 5.8) for 30 to 40 min at 30°C. After spheroplasting was complete, cells were carefully washed twice with 1 ml 1 M sorbitol and twice with 1 ml STC buffer (1 M sorbitol, 10 mM CaCl 2 , 10 mM Tris, pH 7.5) and then harvested at 800 ϫ g for 1 min at 4°C. Spheroplasted cells were resuspended in 1 ml of STC buffer at 4°C.
(ii) Prion particle preparation. of water, 10 ml of 1 M sorbitol, and 1 ml of SCE buffer. Cells were resuspended in 600 l of SCE buffer (containing 1 mM phenylmethylsulfonyl fluoride and protease inhibitor cocktail [Sigma Chemical Co.]) and lysed with 300 l of sterilized glass beads by vortexing 10 times for 10 s each at 4°C. The crude lysate was centrifuged twice at 4°C for 5 min at 800 ϫ g and 1,000 ϫ g. The protein concentration of the supernatant was determined with the Bio-Rad protein assay reagent (Bio-Rad Laboratories). The protein lysate was sonicated three times for 10 s each time prior to transformation (Sonic Dismembrator; Fisher Scientific).
(iii) Transformation procedure. The transformation mixture contained 5 l of pRS316 DNA (ϳ300 ng/l), ϳ300 g of sonicated protein lysate, 10 l of carrier DNA (10 mg/ml), 150 l of spheroplasted cells, and 5 volumes of PEG 8000 buffer (20% [wt/vol] PEG 8000, 10 mM CaCl 2 , 10 mM Tris, pH 7.5) and was incubated for 45 min at 25°C. The transformation mixture was harvested at 1,000 ϫ g and resuspended in 150 l of SOS buffer (1 M sorbitol, 7 mM CaCl 2 , 0.25% yeast extract, and 0.5% Bacto peptone supplemented with 0.3 mg of all of the amino acids in which the yeast strain is deficient) and incubated for 30 min at 30°C. The SOS-cell mixture was plated on SD-ura/sorbitol plates (16.4% sorbitol, 3% glucose, 2% agar, complete supplement mixture without uracil, 0.67% yeast nitrogen base without amino acids) overlaid with top agar (1.2 M sorbitol, 2.5% agar, 2% glucose, complete supplement mixture without uracil, 0.67% yeast nitrogen base without amino acids). The plates were incubated at 30°C for 5 days. Transformants were spotted onto YPD, SD-ade, and 3 mM GdHCl media to score the colonies for the prion state.
RESULTS

Chimeric Sup35-PrP proteins form prions.
To test the effects of the repeat expansion of PrP in a genetically tractable system, we expressed SUP35-PrP chimeras in yeast (Fig. 1) . We replaced the ORD of Sup35p with the wild-type number of 5 PrP repeats and an expanded length of 14 PrP repeats (Fig.  1A) . The chimeric molecules, termed SP5 (for Sup35-PrP 5 repeats) and SP14 (for Sup35-PrP 14 repeats), replaced the wild type by plasmid shuffle and were expressed as the only copy of SUP35. Since SUP35 is essential in yeast, this approach allowed us to evaluate the functionality of the chimeras in the absence of wild-type Sup35p. The expression of the chimeric proteins was similar to endogenous Sup35 protein levels, as determined by Western blotting (Fig. 1B) . A control plasmid with wild-type SUP35 (termed pSup35) was generated and used to ensure that the episomal expression of Sup35p mimicked that of chromosomal Sup35p.
To (Fig. 1C) and could no longer grow on SD-ade medium (data not shown). Moreover, when the chimeras were assessed as the only copy of SUP35 in a [psi Ϫ ] strain, the cells remained red and could not grow on SD-ade medium (data not shown), demonstrating that both chimeras are functional in translation termination. Since the PrP repeat expansion consisting of 14 PrP repeats is pathogenic in humans, we asked if other pathogenic PrP ORD insertions could maintain prion properties in chimeras. Chimeras containing 8 and 11 PrP repeats were created and assayed. These chimeras also behaved phenotypically, biochemically, and genetically as yeast prions (data not shown). Since all of the chimeras were able to maintain the prion state, we analyzed SP5 and SP14 further to determine the effects of repeat expansions on prion properties.
The [SP14 ϩ ] cells displayed more robust growth on SD-ade medium and a lighter pink colony color on YPD in comparison to [SP5 ϩ ] cells (Fig. 1C ). This suggests that the repeat-expanded SP14 protein maintains a stronger prion than SP5. Interestingly, cells with wild-type SUP35 can harbor strain variants of the [PSI ϩ ] prion that display heritable differences in the strength of nonsense suppression without any alteration in amino acid sequence (21) . These changes in nonsense suppression can be phenotypically distinguished in yeast cells harboring the ade1-14 allele as different shades of pink on YPD and different growth rates on SD-ade medium (Fig. 1C) (Fig. 1D) . The presence of soluble protein in the [SP5 ϩ ] prion cells was not unexpected, given the weak nonsense suppression phenotype observed (Fig. 1C) . Lysate from [SP14 ϩ ] cells, however, showed all of the chimeric protein in the pellet fraction, consistent with the stronger nonsense suppression phenotype, and lysate from [sp14 Ϫ ] cells displayed all of the protein in the supernatant (Fig. 1D) .
To further investigate the aggregation of the chimeric prion proteins, the cellular distribution of the chimeric proteins was monitored by GFP fluorescence. An inducible PFD-GFP construct specific for each repeat region (SP5-PFD-GFP or SP14-PFD-GFP) was expressed in the corresponding [ (Fig. 2B) . The SP14/SUP35 [PRION ϩ ] diploid grew on SD-ade medium but displayed both pink and red colonies on YPD, suggesting inefficient inheritance of the nonsense suppression phenotype. Tetrads from the SP14/SUP35 [PRION ϩ ] diploid were spotted onto YPD and SD-ade media to assess inheritance of the prion phenotype in the progeny. The tetrads were also spotted onto selective medium to follow the 2:2 segregation of the sup35 deletion and the presence of SP14. Spores expressing SP14 protein displayed phenotypic variability, as shown in the example tetrad (Fig. 2B) : one light pink colony and one dark pink colony (YPD). The light pink SP14 colony grew better on SD-ade medium than the dark pink colony. Spores containing wildtype SUP35 also inherited the prion phenotype but showed a high degree of instability, as both pink and red colonies were seen on YPD. (Fig. 1C, top two rows) 47) . If the endogenous level of Hsp104p is insufficient to perform this function on the large aggregates of the chimeric proteins, then this could contribute to the observed mitotic instability (4, 5, 29) . Deletion of HSP104 in the chimeras cured the prion phenotype (data not shown), indicating that Hsp104p is required for chimeric prion maintenance. Therefore, we investigated whether the overexpression of Hsp104p would affect their propagation. As expected, overexpression of Hsp104p had a curing effect on wild-type [PSI ϩ ] cells (Fig. 3B, upper right) (10) . However, the overexpression of Hsp104p in [SP14 ϩ ] cells produced primarily pink colonies (Fig. 3B, lower right) . The phenotypic instability in [SP14 ϩ ] cells remained in the empty-vector control, as evident by the frequent appearance of red colonies (Fig. 3B, lower left) . (26) . However, we observed that [SP14 ϩ ] strain variants frequently interconvert between strong and weak nonsense suppression phenotypes (Fig. 4A) . Interconversion was detected by plating a [SP14 ϩ ] culture on YPD and subsequently restreaking isolated colonies. Individual colonies were determined to be strong or weak phenotypically on the basis of colony color (Fig. 4A, first streak ). An individual weak or strong [SP14 ϩ ] colony was selected, resuspended in liquid medium, and plated on YPD. Colonies that started as one phenotype did not maintain the same phenotype in all mitotic progeny (Fig. 4A, second streak) . This suggests that not only does the SP14 protein display multiple prion strain variants, but an individual colony potentially contains more than one self-propagating structure.
Alternatively 5 cells). Thus, if there is increased conformational flexibility in the SP14 protein due to the repeat expansion, it does not enhance the de novo appearance of the prion state. Intriguingly, this result differed from that of the wild-type Sup35p repeat expansion in which a dramatic increase in frequency of prion conversion was observed (31) .
Given this difference, we set out to explore extragenic factors that may play a role in conversion frequency. It is now known that another epigenetic element, [RNQ ϩ ], influences the induction of Sup35p into the prion state (18, 20, 37) (Fig. 4C) . Strikingly, cells containing the SP14 protein converted to [SP14 ϩ ] more frequently (ϳ3 ϫ 10 Ϫ1 ) than cells containing the SP5 protein converted to [SP5 ϩ ] (ϳ6 ϫ 10 Ϫ2 ). This suggests that the repeat expansion does influence the spontaneous prion conversion of the chimeric protein, but only in the presence of another aggregate, [RNQ ϩ ]. Expanded PrP repeats can replace the Sup35p PFD. We observed that the expanded repeat domain in SP14 enables the protein to initiate and propagate many structural conformations, thereby suggesting that the repeat expansion confers enhanced structural flexibility to PrP. Both the PFD of Sup35p and the N terminus of PrP, including the ORD, are highly unstructured regions (42, 51) . The Q/N-rich character of the extreme N terminus of Sup35p has been shown to be critical for the maintenance of [PSI ϩ ] (17). Our initial chimeras characterized retained the Q/N-rich region of the N terminus of Sup35p. Since the SP14 results suggested enhanced conformational flexibility, we asked if the 14-PrP repeats could also replace the essential N-terminal portion of the Sup35p PFD. Therefore, we created a new chimera termed P14MC ( (Fig. 5B) 5E ; also compare SD-ade panels in Fig. 1C and 5A ] cells also showed red and sectoring colonies (Table 1) . Taken together, these results indicate that 14-PrP repeats can replace both the Nterminal Q/N region and the ORD of Sup35p and still maintain prion competence. While the PFD of wild-type Sup35p has a striking 44% Q/N content, the prion-competent P14MC PFD contains only 18% Q/N. This suggests that the structural requirements for a yeast prion protein are not limited by a critical percentage of Q/N residues and that there may be other ways to achieve the structural flexibility required for yeast prion propagation.
DISCUSSION
Here, we describe a novel model system using a chimeric yeast-mammalian prion to evaluate the functionality of the PrP (16) . The 14-PrP repeats also facilitated the establishment and propagation of prion strain variants, as indicated by differences in phenotype, mitotic stability, and prion transmission. Furthermore, in the presence of [RNQ ϩ ], SP14 converted into the prion form more readily than SP5. Strikingly, the 14-PrP repeats replaced the Q/N-rich region and the repeat region of Sup35p and maintained prion properties. Our data suggest that the PrP repeat expansion can influence prion conversion and enhance the formation of multiple aggregate structures.
Strain variants of both yeast prions and PrP Sc are believed to be composed of structurally unique self-propagating aggregates (15, 25, 28, 43) . Although conformationally distinct variants have been associated with PrP Sc strains (2, 3), they have not been associated with inherited PrP mutations. The phenotypic variability associated with some pathogenic point mutations in PrP has been attributed to changes in glycoform ratio, but this did not correlate with the repeat expansion mutations (23) . We suggest that the phenotypic variability observed in inherited repeat expansion prion diseases could result, in part, from differences in the structures acquired by the mutant protein.
Our data show that the repeat-expanded chimera displays phenotypic variation reminiscent of prion strains. The phenotypically distinct [SP14 ϩ ] strain variants exhibited different mitotic stabilities (Fig. 2C) and differential transmission to imperfect prion protein sequences (Table 2) . Taken together, these data suggest that the prions within these variants possess unique characteristics that might be structural, although the nature of the structural differences could not be elucidated. To date, the precise nature of the structural differences in mammalian and yeast prion strain variants also has not been described. A unique feature of the [SP14 ϩ ] strain variants was their enhanced ability to interconvert. Strong variants could spontaneously give rise to weak variants, and vice versa (Fig.  4A ). This observation suggests that the SP14 protein is not entirely committed to one particular prion conformation. There are two possibilities of how the interconversion could arise. First, the [SP14 ϩ ] cells could maintain multiple structures and distinct phenotypes emerge when they separate and multiply (upon restreaking). The phenotype observed in one colony need not indicate structural homogeneity of the chimeric protein, but rather the colony might only show the phenotype of the dominant structure. Second, the SP14 protein may spontaneously create new prion aggregates when the prion state is lost, and these need not be the same strain variant. (Fig. 4B) . However, in the presence of [RNQ ϩ ], the spontaneous conversion of the chimeric proteins was greatly enhanced (Fig. 4C) . This result is similar to that obtained with the Sup35p repeat expansion, which also had a higher frequency of spontaneous conversion in comparison to wild-type Sup35p (31) . We have found that the previously described Sup35p repeat expansion (31) In vitro studies suggest that the repeat expansion in PrP decreases the lag phase of amyloid formation (34) and increases the accessibility of the N terminus of the mutant protein (53), thereby allowing a quicker conformational change into a pathogenic state. Our in vivo model indicates that the spontaneous conversion of the repeat expansion protein to an aggregated state need not be the sole mechanism whereby these mutations affect structure and, ultimately, disease. Instead, the repertoire of conformations achieved by the 14-PrP repeat chimeric protein appeared to be increased. However, in the presence of an additional aggregate, the conversion rate of SP14 was considerably enhanced. Therefore, other misfolded proteins may act as a potential source for initiating a conformational change in the repeat-expanded PrP mutants expressed in the brain. The ORD expansion proteins may interact with other preexisting aggregates to foster a change in conformation or create a high local concentration of the mutant protein which then aggregates.
Our model provides a possible explanation for the behavior of PrP repeat expansions and their propensity not only to cause disease but to contribute to the large degree of phenotypic variability observed in patients. Our data suggest that additional repeats in PrP may allow the formation of multiple unique aggregate conformations that could propagate in different tissues at different rates. In addition, if multiple aggregate structures are present in expanded PrP repeat diseases, then this could offer an explanation as to why infectious aggregate structures may also be produced in some cases (7) but not others (8, 14, 45) . When we investigated the interaction between SP5 and SP14 by analyzing strains expressing both chimeras, indeed, we did observe a wide range of phenotypes (data not shown). Previous analyses of repeat expansion mutants isolated from human brain tissue demonstrated coaggregation with wild-type PrP, suggesting that phenotypic variability might be explained by the extent of this association (9) . We suggest that differential association of mutant and wild-type PrP might be a consequence of different structures of the repeat expansion-containing PrP. Thus, while other genetic modifiers may play a role in disease variability, at least some of the phenotypic variability observed with PrP repeat expansion diseases may be based on intragenic features of the mutant.
